EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
135.95
-1.62 (-1.18%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close137.57
Open137.50
Bid0.00 x 1100
Ask148.50 x 1100
Day's Range135.25 - 137.82
52 Week Range100.20 - 143.22
Volume1,002,330
Avg. Volume1,376,973
Market Cap28.655B
Beta0.70
PE Ratio (TTM)52.33
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters3 days ago

    Medtronic beats estimates on cardio, diabetes gains

    Medtronic Plc topped analysts' estimates for profit in the fourth quarter as it kept a tight lid on costs and upped sales of its heart valves and insulin pumps, offsetting the impact of hurricane damage to production in Puerto Rico. "Relative to nervousness that investors have come to expect around Medtronic's earnings releases, we thought the fourth-quarter print was solid," Evercore ISI analyst Vijay Kumar said. Sales across Medtronic's business units beat analysts' estimates, according to Thomson Reuters I/B/E/S, and the company forecast an adjusted profit of $5.10 to $5.15 per share for fiscal 2019 compared to expectations of $5.14.

  • Why Is Edwards Lifesciences (EW) Up 1.5% Since Its Last Earnings Report?
    Zacks3 days ago

    Why Is Edwards Lifesciences (EW) Up 1.5% Since Its Last Earnings Report?

    Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • The Wall Street Journal6 days ago

    [$$] The AI Doctor Will See You Now

    The NeuroPace Responsive Neurostimulation System “literally provides peace of mind I never imagined could exist,” she said. Armed with the knowledge of what worked before, the system instructs the implant to stimulate users’ brains to interrupt a seizure at its onset. The innovation is part of a larger phenomenon that has big implications for how we identify and treat disease: the introduction of artificial intelligence to consumer and clinical electronics.

  • A Look at Abbott Laboratories’ Valuation Multiples
    Market Realist19 days ago

    A Look at Abbott Laboratories’ Valuation Multiples

    On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.

  • New Product Launches Drive ABT’s Medical Device Business
    Market Realist23 days ago

    New Product Launches Drive ABT’s Medical Device Business

    (Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments.  ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...

  • ABT’s Medical Devices Business: A Key Growth Driver
    Market Realist23 days ago

    ABT’s Medical Devices Business: A Key Growth Driver

    On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates. 

  • ABT’s Recent Stock Slump: What’s behind the Decline?
    Market Realist24 days ago

    ABT’s Recent Stock Slump: What’s behind the Decline?

    On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.

  • Analysts’ Recent Recommendations and Target Price for ABT Stock
    Market Realist24 days ago

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.

  • Barrons.comlast month

    [$$] Positive Analyst Reports on Edwards Lifesciences, Twitter, and PulteGroup

    Capital One Financial • COF-NYSE Underperform • Price $97.42 on April 24 by Evercore ISI The bank holding company, which focuses on credit cards, auto loans, savings, and other accounts reported first-quarter 2018 earnings per share from continuing operations of $2.61. Setting aside its restructuring charges and securities gains, we peg core earnings at $2.63, versus our estimate of $2.40 and the consensus estimate of $2.33. Overall, it was a relatively solid quarter, marked by better deposit growth, slightly better loans/receivables growth, and higher interchange fees.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of EW earnings conference call or presentation 24-Apr-18 9:00pm GMT

    Q1 2018 Edwards Lifesciences Corp Earnings Call

  • Associated Presslast month

    Edwards Lifesciences, General Dynamics slip; Comcast rises

    Stocks that moved substantially or traded heavily Wednesday: Comcast Corp., up 91 cents to $34.26 The cable company had a solid first quarter and offered to buy U.K. broadcaster Sky for $30 billion. Texas ...

  • Edwards CEO Mike Mussallem Driven By Passion For Helping Others
    Investor's Business Dailylast month

    Edwards CEO Mike Mussallem Driven By Passion For Helping Others

    Motivated by a goal to create meaning in his work, Edwards Lifesciences[ticker symb=EW] CEO Mike Mussallem pushed boundaries to follow his passion for helping people live their best lives. In the process, Mussallem and his team have transformed Edwards into the global leader in patient-focused innovations for structural heart disease, as well as critical care and surgical monitoring. Mussallem believes...

  • Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss
    Zackslast month

    Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss

    Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.

  • Premarket: Futures Improve As Boeing, Twitter, 3 Chip Stocks Soar
    Investor's Business Dailylast month

    Premarket: Futures Improve As Boeing, Twitter, 3 Chip Stocks Soar

    Premarket trading turned mixed on Wednesday as Boeing, Twitter and Cree gained, Alphabet got an upgrade and Comcast bid $31 billion for Britain's Sky.

  • What Drove Edwards Lifesciences’ 1Q18 Earnings?
    Market Realistlast month

    What Drove Edwards Lifesciences’ 1Q18 Earnings?

    Japan is the company’s highest growth region outside the United States. Therapy adoption continues to be the major factor driving Edwards’ THVT segment sales in 1Q18. For more on related developments, read Recent Developments at Edwards Lifesciences.

  • Edwards Lifesciences Missed Sales Estimates in 1Q18
    Market Realistlast month

    Edwards Lifesciences Missed Sales Estimates in 1Q18

    Edwards Lifesciences Stock Fell on Missed 1Q18 Sales EstimatesEdwards Lifesciences releases 1Q18 results

  • InvestorPlacelast month

    3 Stocks to Watch on Wednesday: Edwards Lifesciences Corp (EW), Illumina, Inc. (ILMN) and Tesla Inc (TSLA)

    Edwards Lifesciences Corp (NYSE:EW) and Illumina, Inc. (NASDAQ:ILMN) reported their quarterly earnings results after hours Tuesday, while Tesla Inc (NASDAQ:TSLA) finds itself in hot waters over a contract dispute. Edward Lifesciences reported its latest quarterly results after hours yesterday. The company announced that the first-quarter global sales of its heart valves, a metric that marks the company’s most important growth driver, increased 2.3% year-over-year to $551.5 million.

  • Reuterslast month

    Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

    Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc. The company's shares fell as much as 8.1 percent in after-market trading as sales of its premium non-invasive device, used to replace diseased aortic valves without open-heart surgery, is its biggest growth driver. "Procedure growth in Europe was double digits this quarter, while our growth was lower due to a year-over-year shift in share to our largest competitor," Chief Executive Officer Michael A. Mussallem said on a call with analysts.

  • MarketWatchlast month

    Edwards Lifesciences stock drops 8% after forecast misses

    Edwards Lifesciences Corp. shares dropped in late trading Tuesday after the company provided a disappointing forecast. The company reported first-quarter earnings of 96 cents a share on sales of $894.8 ...

  • Despite Today's Market, Baozun And Solaredge Technologies Join Sector Leaders
    Investor's Business Dailylast month

    Despite Today's Market, Baozun And Solaredge Technologies Join Sector Leaders

    Here’s a list of all the top-rated growth stocks that have just been added to the IBD 50, IBD Big Cap 20, Sector Leaders, Stock Spotlight and IPO leaders.

  • Edwards Lifesciences Tanks After Heart-Valve Sales Lag Expectations
    Investor's Business Dailylast month

    Edwards Lifesciences Tanks After Heart-Valve Sales Lag Expectations

    For the first quarter, Edwards reported $937.5 million in adjusted sales and adjusted profit of $1.22 per share.

  • CNBClast month

    After-hours buzz: TXN, WYNN, EW & more

    See which stocks are posting big moves after the bell.

  • The Hottest Earnings Charts This Week
    Zackslast month

    The Hottest Earnings Charts This Week

    All eyes will be on these hot stocks during this busy earnings week.

  • Edward Life Sciences drops on mixed earnings release
    CNBC Videoslast month

    Edward Life Sciences drops on mixed earnings release

    CNBC's Kate Rogers reports on the quarterly earnings for Edward Life Sciences.